Prostate cancer: Genomic drivers of resistance to AR therapies

被引：6
|
作者：
Kelsey R.
机构：
来源：
Nature Reviews Urology | 2018年 / 15卷 / 4期
关键词：
D O I：
10.1038/nrurol.2018.18
中图分类号：
学科分类号：
摘要：
[No abstract available]
引用
收藏
页码：202 / 202
相关论文
共 50 条
  • [41] Re: AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer
    Anand, Aseem Undvall
    Bjartell, Anders
    EUROPEAN UROLOGY, 2015, 67 (02) : 349 - 350
  • [42] Re: AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer
    Taneja, Samir S.
    JOURNAL OF UROLOGY, 2015, 193 (02): : 538 - 538
  • [43] Re: AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer
    Sun, Maxine
    Abdollah, Firas
    EUROPEAN UROLOGY, 2015, 68 (01) : 162 - 163
  • [44] Complementary therapies in prostate cancer
    Eylert, Maike F.
    Persad, Raj
    TRENDS IN UROLOGY & MENS HEALTH, 2011, 2 (03) : 17 - 22
  • [45] Targeted therapies for prostate cancer
    Asatiani, E
    Gelmann, EP
    EXPERT OPINION ON THERAPEUTIC TARGETS, 2005, 9 (02) : 283 - 298
  • [46] Novel therapies in prostate cancer
    Turkeri, LN
    EUROPEAN UROLOGY SUPPLEMENTS, 2004, 3 (03) : 63 - 69
  • [47] New therapies for prostate cancer?
    Tanowitz, Herbert B.
    Machado, Fabiana S.
    CANCER BIOLOGY & THERAPY, 2010, 10 (04) : 326 - 328
  • [48] Targeted Therapies for Prostate Cancer
    Petrioli, Roberto
    Francini, Edoardo
    Fiaschi, Anna Ida
    Laera, Letizia
    Roviello, Giandomenico
    CANCER INVESTIGATION, 2015, 33 (07) : 276 - 285
  • [49] Androgen Receptor Rearrangement and Splicing Variants in Resistance to Endocrine Therapies in Prostate Cancer
    Ho, Yeung
    Dehm, Scott M.
    ENDOCRINOLOGY, 2017, 158 (06) : 1533 - 1542
  • [50] Resistance to Novel Antiandrogen Therapies in Metastatic Castration-Resistant Prostate Cancer
    Boudadi, Karim
    Antonarakis, Emmanuel S.
    CLINICAL MEDICINE INSIGHTS-ONCOLOGY, 2016, 10 : 1 - 9
12345